RRM2 and cancer: Almost all the FRGs in signaling pathways of pan-cancer, STMN1, RRM2, HELLS, FANCD2, and AURKA could significantly activate the cell cycle, but inhibit EMT, DNA damage response, hormones ER, RAS/MAPK, and RTK (Figure 2(e)).